PHARMACY

PPD selected as exclusive partner by DiabetesAmerica

BY Allison Cerra

WILMINGTON, N.C. PPD has entered into an exclusive alliance with DiabetesAmerica, a provider of comprehensive diabetes care services based in Houston, Texas.

Under the agreement, PPD will provide clinical research training and support to more than 20 clinical trial investigators who will conduct Type 1 and Type 2 diabetes clinical trials from DiabetesAmerica’s 17 centers across Texas and Arizona.

Additionally, DiabetesAmerica will work exclusively with PPD to provide clinical research services for endocrine and metabolic disease development programs over a minimum of three years. The agreement expands PPD’s ability to recruit for diabetes-related clinical trials through the use of DiabetesAmerica’s 16,000-plus patient database.

“Diabetes is a disease with serious complications that affects more than 23 million Americans,” said Mike Wilkinson, EVP clinical development at PPD. “We are pleased to assist these physicians in bringing cutting-edge diabetes treatments to their patients through training and support. In addition, DiabetesAmerica’s patient database expands our ability to offer clinical trial options to a broader population of people living with this increasingly common disease.”

Founded in 2004, DiabetesAmerica currently treats nearly 20,000 patients with Type 1 and Type 2 diabetes. It offers a unique, comprehensive approach to diabetes treatment, with each of its health centers providing personalized medical care and education, nutrition and lifestyle needs at the same facility by a dedicated, experienced team of medical, nutrition and nursing professionals.

“DiabetesAmerica is committed to delivering the latest treatments in diabetes care to our patients,” said Rosemary Mazanet, M.D., Ph.D., and CEO of DiabetesAmerica. “Our alliance with PPD will help ensure our physicians are fully trained on managing drug development programs so we can continue to bring complete diabetes care to our patients.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

New report questions glucose self-monitoring among noninsulin-dependent Type 2 diabetes patients

BY Alaric DeArment

NEW YORK There’s no proof that self monitoring of blood glucose by Type 2 diabetes patients not dependent on insulin produces any benefits, according to a recent report by a German healthcare analysis organization.

The Institute for Quality and Efficiency in Health Care also said in its report that it remained unclear whether blood tests had an advantage over urine tests. Blood glucose monitoring remains important for Type 1 and Type 2 patients who do inject insulin, the report noted.

The report by IQWiG — the organization bases its acronym on its German name — used six trials, but came to the conclusion that the data from the trials were not enough to draw any conclusions on the long-term benefit of glucose self-monitoring among noninsulin-dependent Type 2 diabetes patients.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Former CDC head assumes new role at Merck’s vaccine division

BY Alaric DeArment

WHITEHOUSE STATION, N.J. The former head of the Centers for Disease Control and Prevention will soon start work as the new president of Merck & Co.’s vaccine division.

Merck announced Monday that it had appointed Julie Gerberding as president of Merck Vaccines, effective Jan. 25. Gerberding was director of the CDC from 2002 to 2009, having led the agency through more than 40 emergency response initiatives for health crises.

“Vaccines are a cornerstone of Merck’s commitment to health and wellness,” Merck chairman and CEO Richard Clark said. “We are delighted to welcome an expert of Dr. Gerberding’s caliber to Merck.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?